Replies to post #240770 on Biotech Values

[DewDiligence]

ABUS inks Greater-China* development deal for AB-729—$40M up-front cash:

https://finance.yahoo.com/news/arbutus-qilu-pharmaceutical-enter-exclusive-123000244.html

AB-729, an injected RNAi agent that targets HBsAg (HBV surface antigen), is a drug candidate I’ve been generally unimpressed with (e.g. #msg-164615657).

However, the most notable aspect of the above deal (IMO) is that it does not include AB-806, ABUS’ core inhibitor (#msg-167079537).

*China, Hong Kong, Macau, Taiwan.